EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Criteria and non-criteria antiphospholipid autoantibodies screening in patients with late pregnancy morbidity: A cross-sectional study

Clothilde Gros, Arthur Mageau, Tiphaine Barral, Pascale Roland Nicaise, Marie-Hélène Saint-Frison, Margot Bucau, Valérie Vivier, Valentine Marie Ferre, Agnès Bourgeois-Moine, Thomas Papo, Tiphaine Goulenok, Karim Sacre

Placenta · 2024

DOI: 10.1016/j.placenta.2024.06.019 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Placenta, 2024. Verfasst von Clothilde Gros und 11 weiteren Autor:innen. Beteiligte Einrichtung: Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France. Hauptthemen laut MEDLINE: Antibodies, Antiphospholipid, Antiphospholipid Syndrome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Assistance Hospitals Paris, University Paris Cité.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Antiphospholipid syndrome (APS) is a cause of pregnancy morbidity. We aim to determine the frequency of criteria and non-criteria anti-phospholipid (aPL) autoantibodies in patients admitted for unexplained fetal death (UFD), pre-eclampsia (PE) and/or fetal growth restriction (FGR). METHODS: All consecutive patients with UFD, PE and/or FGR followed in the department of Obstetrics, Bichat Hospital, University of Paris, Paris, between January 2019 and December 2021 were screened. Patients with available serum stored from the index pregnancy were included. Patients with previously known APS or twin pregnancy were excluded. Testing for aPL autoantibodies included anti-cardiolipin (aCL), anti-β2GPI (aβ2GPI), anti-phosphatidylethanolamine (aPE), anti-phosphatidylserine/prothrombin (aPS/PT) IgG/IgM and anti-annexin V IgG. When available, placenta specimens were analyzed by a pathologist blinded to the aPL status. All clinical characteristics, pregnancy features, and comorbidities were extracted from electronic medical records. RESULTS: Overall 167 (32 (28.8-35.7) years) patients with UFD (n = 28; 16.8 %), PE (n = 60; 35.9 %) and/or FGR (n = 105; 62.9 %) were screened for aPL autoantibodies. Moderate titers of aPL autoantibodies were detected in 33 (n = 33/167, 19.8 %) patients. aPL autoantibodies were non-criteria aPE IgG/IgM in most cases (n = 28/33, 84.8 %). aPS/PT IgG/IgM were found in 11 (n = 11/33, 33.3 %) cases and aCL or aβ2GP1 IgG/IgM in 4 (n = 4/33, 12.1 %). Multivariable logistic regression showed that aPL autoantibodies were mostly associated with UFD (OR 4.37 [1.72-11.20], p = 0.002), PE ≤ 34th week of gestation (3.22 [0.86-11.90], p = 0.070) and chronic deciduitis (8.03 [0.89-67.2], p = 0.060) DISCUSSION: The frequency of aPL autoantibodies, mostly aPE, is high in patients with late pregnancy morbidity and may qualify obstetrical APS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, AntiphospholipidAntiphospholipid SyndromeHumansFemalePregnancyAdultCross-Sectional StudiesFetal Growth RetardationFetal DeathPre-EclampsiaPregnancy Complications

Stichwörter der Autor:innen

Antiphospholipid antibodiesClassificationPhosphatidylethanolaminesPregnancy complications: fetal death

Substanzen

Antibodies, Antiphospholipid

Autor:innen und Institutionen

  • Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France.
  • Département de Gynécologie Obstétrique, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France.
  • Département d' Immunologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France.
  • Unité de Fœtopathologie Département de Génétique, Hôpital Robert Debré, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France.
  • Département de Pathologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France.
  • Département de Virologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France.

Förderung

  • Public Assistance Hospitals Paris
  • University Paris Cité

Zitieren

APA

Gros, C., Mageau, A., Barral, T., Nicaise, P. R., Saint-Frison, M. H., Bucau, M., Vivier, V., Ferre, V. M., Bourgeois-Moine, A., Papo, T., Goulenok, T., & Sacre, K. (2024). Criteria and non-criteria antiphospholipid autoantibodies screening in patients with late pregnancy morbidity: A cross-sectional study. Placenta. https://doi.org/10.1016/j.placenta.2024.06.019

Vancouver

Gros C, Mageau A, Barral T, Nicaise PR, Saint-Frison MH, Bucau M, et al. Criteria and non-criteria antiphospholipid autoantibodies screening in patients with late pregnancy morbidity: A cross-sectional study. Placenta. 2024. doi:10.1016/j.placenta.2024.06.019

BibTeX
@article{Gros2024,
  author = {Gros, Clothilde and Mageau, Arthur and Barral, Tiphaine and Nicaise, Pascale Roland and Saint-Frison, Marie-Hélène and Bucau, Margot and Vivier, Valérie and Ferre, Valentine Marie and Bourgeois-Moine, Agnès and Papo, Thomas and Goulenok, Tiphaine and Sacre, Karim},
  title = {Criteria and non-criteria antiphospholipid autoantibodies screening in patients with late pregnancy morbidity: A cross-sectional study},
  journal = {Placenta},
  year = {2024},
  doi = {10.1016/j.placenta.2024.06.019}
}
Kostenlos starten →